Centessa Pharmaceuticals PLC ADR

Yahoo Finance • 22 days ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of o... Full story

Yahoo Finance • 3 months ago

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Argus upgraded Warner Bros. Discovery... Full story

Yahoo Finance • 4 months ago

LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential. On September 9, LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Centessa Pharmaceuticals and set a price targe... Full story

Yahoo Finance • 5 months ago

Centessa rated Outperform at Oppenheimer on ORX750 potential

[Wall Street New York stock exchange stock market] alexsl Centessa Pharmaceuticals (NASDAQ:CNTA [https://seekingalpha.com/symbol/CNTA]) has been rated as Outperform at Oppenheimer, reflecting strong conviction in the company's lead asset,... Full story

Yahoo Finance • 5 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idi... Full story

Yahoo Finance • 6 months ago

Thermo Fisher Scientific Inc Sees Significant Reduction in Eaton Vance Worldwide Health ...

Insights from the Fund's Second Quarter 2025 N-PORT Filing Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, revealing strategic investment decisions made d... Full story

Yahoo Finance • 6 months ago

Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a $2.06 billion market cap biotech company, sold 10,000 ordinary shares on July 25, 2025, for $155,598. The shares were sold at prices ranging from... Full story

Yahoo Finance • 6 months ago

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist. Continue Reading View Comments... Full story

Yahoo Finance • 7 months ago

Centessa Pharma (CNTA) CBO Weinhoff sells $138k in shares

Centessa Pharmaceuticals PLC (NASDAQ:CNTA) Chief Business Officer Gregory M. Weinhoff sold 10,000 ordinary shares of the company on June 25, 2025, for a total of $138,642. The shares were sold at prices ranging from $13.60 to $14.06. On th... Full story

Yahoo Finance • 7 months ago

Centessa Pharmaceuticals' Accardi sells $210,000 in shares

Mario Alberto Accardi, President, Orexin Program at Centessa Pharmaceuticals PLC (NASDAQ:CNTA), sold 15,000 ordinary shares of the company on June 24, 2025, for $14.00 each, totaling $210,000. The transaction comes as the stock has shown s... Full story

Yahoo Finance • 7 months ago

Centessa Pharma CEO Saha sells $694,826 in shares

Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a biotech company with a market capitalization of $1.69 billion, saw its Chief Executive Officer Saurabh Saha sell 55,000 ordinary shares of the company on June 20, 2025, for a total of $694,826.... Full story

Yahoo Finance • 7 months ago

Alkermes upgraded at UBS on prospects for sleep disorder therapy

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images UBS upgraded Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor (OX2R) ag... Full story

Yahoo Finance • 7 months ago

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a... Full story

Yahoo Finance • 8 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that memb... Full story

Yahoo Finance • 8 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idi... Full story

Yahoo Finance • 8 months ago

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against other top small cap stocks to buy... Full story

Yahoo Finance • 10 months ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopa... Full story

Yahoo Finance • 10 months ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announce... Full story